NCT03754309View on ClinicalTrials.gov

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL

Enrollment

89

Participants

Timeline

Start Date

December 13, 2018

Primary Completion Date

May 12, 2020

Study Completion Date

October 8, 2020

Conditions

Dermatitis, Atopic

Interventions

DRUG

KY1005

A human anti-OX40 ligand monoclonal antibody

DRUG

Placebo

Matched placebo

Trial Locations (19)

Unknown

Kymab investigational site 106, Kiel

Kymab investigational site 113, Leipzig

Kymab investigational site 207, Gdansk

Kymab investigational site 216, Katowice

Kymab investigational site 206, Krakow

Kymab investigational site 212, Krakow

Kymab investigational site 213, Krakow

Kymab investigational site 214, Krakow

Kymab investigational site 203, Olsztyn

Kymab investigational site 210, Poznan

Kymab investigator site 201, Rzeszów

Kymab investigational site 204, Warsaw

Kymab investigational site 202, Wroclaw

Kymab investigational site 304, Córdoba

Kymab investigational site 303, Madrid

Kymab investigational site 302, Seville

Kymab investigational site 315, Valencia

Kymab investigational site 420, Harrogate

Kymab investigational site 402, Sheffield

All Listed Sponsors

lead

Kymab Limited

INDUSTRY

NCT03754309 - A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter